ArticleThe Lancet regional health. Southeast Asia2023

Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study.

Prasad S Kulkarni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.